The New England Journal of Medicine
All Products
Metabolic Research Compound
Retatrutide
Triple AgonistGLP-1 / GIP / Glucagon
High-purity Retatrutide peptide for research applications.
Vial Size
From
$45.00
Bundle & Save
Free shipment protection
We acceptPay
Research use only
Compound Information
Technical specifications
Molecular Profile
What is Retatrutide?
Triple-agonist research compound targeting GLP-1, GIP, and glucagon receptors. Studied for metabolic and weight regulation pathways.
- Type
- Triple-agonist peptide (GLP-1 / GIP / Glucagon)
- Molecular Weight
- ~4731 g/mol
- Amino Acids
- 39 (modified)
Storage Requirements
Stability Information
Protect from lightAvoid repeated freeze-thaw
Lyophilized (powder)
-20°C·up to 2 years
After opening
2-8°C·use within 30 days
Mechanism of Action
Retatrutide simultaneously engages three incretin and energy-balance receptors — GLP-1, GIP, and glucagon. GLP-1/GIP activation enhances glucose-dependent insulin secretion and satiety signaling, while glucagon-receptor activity is hypothesized to drive additional energy expenditure via hepatic and brown-adipose pathways.
Areas of Research
Body-mass and adiposity modulation models
Glycemic control and insulin sensitivity
Hepatic lipid metabolism (NAFLD/MASH research)
Energy expenditure and thermogenesis
Appetite and satiety neural pathways
Purity
≥ 99% by independent third-party HPLC. Endotoxin tested. Lyophilized under sterile conditions.
Half-Life
~6 days
Solubility
Freely soluble in standard aqueous diluents
Sources & References
Peer-reviewed research
The Lancet
Triple hormone receptor agonist retatrutide for type 2 diabetes — Phase 2 trial
2023·PMID: 37356473
Rosenstock J et al.
Nature Medicine
Retatrutide effects on hepatic steatosis in adults with obesity
2024
Sanyal AJ et al.
About this compound
Overview
Retatrutide is a synthetic peptide studied as a triple receptor agonist, acting on the GLP-1, GIP, and glucagon receptors. This combined activity at three metabolic receptors is what distinguishes it from single- and dual-agonist research peptides, and it is the focus of considerable interest in metabolic research. PX-Labs supplies Retatrutide as a lyophilized powder for laboratory research use only.
Background
Within the incretin class of research peptides, compounds are often categorized by how many receptors they target. Single agonists act at GLP-1; dual agonists such as tirzepatide add GIP activity. Retatrutide is studied as a triple agonist, adding glucagon-receptor activity to the other two. Researchers investigating comparative receptor activity frequently group it alongside semaglutide and tirzepatide for that reason.
Specifications
- Compound
- Retatrutide (triple GLP-1 / GIP / glucagon receptor agonist)
- Form
- Lyophilized powder, sealed vial
- Purity
- ≥98%, verified by HPLC
- Testing
- Independent third-party analysis; COA available on request
- Available sizes
- 5mg, 10mg, 30mg
- Presentation
- Lyophilized powder in a sealed research vial
Handling & Storage
In its lyophilized form, Retatrutide is generally stored refrigerated and protected from light and moisture, with freezer storage common for longer-term holding. Standard laboratory handling practices apply.
Purity & Testing
Every batch is tested to a minimum of 98% purity by high-performance liquid chromatography, with analysis performed by an independent laboratory so results remain impartial. A Certificate of Analysis reporting identity, purity, and method is available on request.
Research Use Only
Retatrutide is sold strictly for laboratory and scientific research. It is not intended for human or veterinary use, and PX-Labs is a research chemical supplier, not a compounding pharmacy. PX-Labs does not provide usage or application guidance.